- Trials with a EudraCT protocol (1,184)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
1,184 result(s) found for: Long bone.
Displaying page 1 of 60.
EudraCT Number: 2009-009374-27 | Sponsor Protocol Number: 20080540 | Start Date*: 2009-08-27 | |||||||||||
Sponsor Name:Amgen Inc | |||||||||||||
Full Title: An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab in the Treatment of Bone Metastases in Subjects with Advanced Cancer or Multiple Myeloma | |||||||||||||
Medical condition: Bone metastases in subjects with advanced cancer or multiple myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001458-14 | Sponsor Protocol Number: P130921 | Start Date*: 2015-10-01 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: | |||||||||||||
Medical condition: | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-012189-30 | Sponsor Protocol Number: BC1-09 | Start Date*: 2009-10-30 | |||||||||||
Sponsor Name:Algeta ASA | |||||||||||||
Full Title: An open-label Phase IIa, non-randomised, study of Alpharadin in breast cancer patients with bone dominant disease who are no longer considered suitable for endocrine therapy | |||||||||||||
Medical condition: Breast cancer patients with bone dominant disease who have progressed on endocrine therapy and are no longer considered suitable for further endocrine therapy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: BE (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001758-32 | Sponsor Protocol Number: 20140114 | Start Date*: 2017-08-29 |
Sponsor Name:Amgen, Inc. | ||
Full Title: Long-term Safety Follow-up of Subjects With Giant Cell Tumour of Bone Treated With Denosumab in Study 20062004 | ||
Medical condition: Giant Cell Tumour of Bone | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing) PL (Completed) FR (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-006195-11 | Sponsor Protocol Number: BC1-06 | Start Date*: 2008-03-26 | |||||||||||
Sponsor Name:Algeta ASA | |||||||||||||
Full Title: A double-blind, randomised, multiple dose, Phase III, multicentre study of Alpharadin in the treatment of patients with symptomatic hormone refractory prostate cancer with skeletal metastases. | |||||||||||||
Medical condition: Hormone refractory prostate cancer with skeletal metastases | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: SE (Completed) FR (Completed) GB (Completed) BE (Completed) SK (Completed) ES (Completed) CZ (Completed) NL (Completed) IT (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004939-39 | Sponsor Protocol Number: GS-EU-174-1403 | Start Date*: 2015-05-26 | |||||||||||
Sponsor Name:Gilead Sciences International Ltd. | |||||||||||||
Full Title: Pharmacoepidemiology study to define the long-term safety profile of tenofovir disoproxil fumarate (Tenofovir DF, Viread®) and describe the management of Tenofovir DF-associated renal and bone toxi... | |||||||||||||
Medical condition: Chronic Hepatitis B | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) GB (Prematurely Ended) ES (Prematurely Ended) BG (Prematurely Ended) GR (Completed) FR (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-006726-34 | Sponsor Protocol Number: Anti TNF- aGvHD | Start Date*: 2009-02-23 | |||||||||||
Sponsor Name:ISTITUTO GIANNINA GASLINI | |||||||||||||
Full Title: Anti-TNF monoclonal antibody to treat acute GvHD refractary to the first line therapy with steroids | |||||||||||||
Medical condition: Anti-TNF monoclonal antibody to treat acute GvHD refractary to the first line therapy with steroids | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-001041-17 | Sponsor Protocol Number: 20060289 | Start Date*: 2007-09-11 | |||||||||||
Sponsor Name:Amgen Inc. | |||||||||||||
Full Title: An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety and Sustained Efficacy of Denosumab (AMG162) in the Treatment of Postmenopausal Osteoporosis | |||||||||||||
Medical condition: Treatment of postmenopausal osteoporosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: DK (Completed) SE (Completed) EE (Completed) DE (Completed) LV (Completed) GB (Completed) LT (Completed) HU (Completed) AT (Completed) FI (Completed) BE (Completed) MT (Completed) CZ (Completed) FR (Completed) ES (Completed) GR (Completed) IT (Completed) BG (Completed) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-005096-27 | Sponsor Protocol Number: MBPS205 | Start Date*: 2017-06-23 | |||||||||||
Sponsor Name:Mereo BioPharma 3 Ltd. | |||||||||||||
Full Title: A Phase 2b, Multicentre, Multinational, Double-blind, Dose-finding Study, incorporating an open label substudy, in Adult Patients with Type I, III or IV Osteogenesis Imperfecta Treated with setrusu... | |||||||||||||
Medical condition: Osteogenesis imperfecta | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) GB (GB - no longer in EU/EEA) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-001666-40 | Sponsor Protocol Number: CZOL446H2202E1 | Start Date*: 2005-02-01 |
Sponsor Name:Novartis Pharma AG | ||
Full Title: An international, multicenter, randomized, open-label, safety and efficacy trial of intravenous zoledronic acid administered either once or twice yearly in children with severe osteogenesis imperfe... | ||
Medical condition: Osteogenesis Imperfecta | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: HU (Prematurely Ended) GB (Completed) BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-001606-16 | Sponsor Protocol Number: 20062004 | Start Date*: 2009-01-16 | |||||||||||
Sponsor Name:Amgen Inc | |||||||||||||
Full Title: An Open-label, Multi-center, Phase 2 Study of Denosumab in Subjects with Giant Cell Tumor of Bone | |||||||||||||
Medical condition: Giant cell tumor of bone (GCTB) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) DE (Completed) AT (Completed) FR (Completed) ES (Completed) GB (Completed) PL (Completed) IT (Completed) SE (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-000431-32 | Sponsor Protocol Number: ORTHOUNION | Start Date*: 2017-05-25 | ||||||||||||||||
Sponsor Name:Universidad Autónoma de Madrid (U.A.M.) | ||||||||||||||||||
Full Title: A MULTI-CENTRE, OPEN-LABEL, RANDOMIZED, COMPARATIVE CLINICAL TRIAL OF TWO DIFFERENT DOSES OF BONE MARROW AUTOLOGOUS HUMAN MESENCHYMAL STEM CELLS PLUS BIOMATERIAL VERSUS ILIAC CREST AUTOLOGOUS GRAFT... | ||||||||||||||||||
Medical condition: Diaphyseal and/or metaphysodiaphyseal fractures (femur, tibia, humerus) with status of non-union | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Ongoing) DE (Completed) FR (Ongoing) IT (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-000618-23 | Sponsor Protocol Number: ORN-01 | Start Date*: 2015-05-05 | ||||||||||||||||
Sponsor Name:Västra Götalandsregionen/NÄL | ||||||||||||||||||
Full Title: Treatment of osteoradionecrosis (ORN) with pentoxifylline and α-tocopherol (PENTO) | ||||||||||||||||||
Medical condition: Osteoradionecrosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: SE (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-000887-32 | Sponsor Protocol Number: ORN-02 | Start Date*: 2015-07-20 | ||||||||||||||||
Sponsor Name:Västra Götalandsregionen/NÄL | ||||||||||||||||||
Full Title: Prophylactic treatment of osteoradionecrosis (ORN) with pentoxifylline and α-tocopherol (PENTO) | ||||||||||||||||||
Medical condition: Osteoradionecrosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: SE (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-002418-12 | Sponsor Protocol Number: CFEM345D2407 | Start Date*: 2005-01-25 |
Sponsor Name:Novartis Pharma Services AG | ||
Full Title: An open-label, randomized, multicenter safety study to evaluate the skeletal and lipid profile effects of letrozole and tamoxifen in postmenopausal women with resected, receptor positive early brea... | ||
Medical condition: Bone loss attributed to cessation of ovarian estrogen production is common in postmenopausal women. In postmenopausal women with breast cancer, treatment with an aromatase inhibitor may further red... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: DK (Completed) GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-004840-21 | Sponsor Protocol Number: RISED_C_00935 | Start Date*: 2007-04-23 | |||||||||||
Sponsor Name:sanofi-aventis Netherlands B.V. | |||||||||||||
Full Title: Bone Histomorphometry, Microarchitecture and Matrix Structure and Properties in Patients Receiving Long-term Risedronate Treatment | |||||||||||||
Medical condition: The objective of this study is to collect data on bone histomorphometry, architecture, turnover and material properties from iliac crest biopsies taken from postmenopausal women after > 5 year rise... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000075-16 | Sponsor Protocol Number: BAY88-8223/16216 | Start Date*: 2012-06-20 | |||||||||||
Sponsor Name:Bayer HealthCare AG | |||||||||||||
Full Title: Radium-223 Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients with Bone Metastasis | |||||||||||||
Medical condition: Castrate Resistant Prostate Cancer/Hormone-Refractory Prostate Cancer patients with bone metastasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: SE (Completed) DE (Completed) NO (Completed) FI (Completed) BE (Completed) ES (Completed) CZ (Completed) IE (Completed) GB (Completed) IT (Completed) DK (Prematurely Ended) NL (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-004729-25 | Sponsor Protocol Number: 9741 | Start Date*: 2006-04-14 |
Sponsor Name:R & D Directorate,Central Manchester and Manchester Children's University Hospitals NHS Trust | ||
Full Title: A pilot randomised controlled trial to determine if vitamin D treatment will result in a greater bone mass acquisition in pubertal girls | ||
Medical condition: Hypovitaminosis D in healthy subjects / Subclinical vitamin D deficiency. Recently there have been many reports of vitamin D deficiency in healthy adolescents worldwide. It is not yet known wheth... | ||
Disease: | ||
Population Age: Adolescents, Under 18 | Gender: Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-004104-30 | Sponsor Protocol Number: 307-MET-9002-0009 | Start Date*: 2015-04-01 |
Sponsor Name:Pharmacia & Upjohn S.A. | ||
Full Title: Treatment With Recombinant Human Growth Hormone (Genotonorm) in Children With Short Stature Secondary to a Long Term Corticoid Therapy. A Study of Efficacy and Safety | ||
Medical condition: Juvenile idiopathic arthritis (JIA) and nephrotic syndrome (NeS) | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2022-002241-18 | Sponsor Protocol Number: 983.974.742 | Start Date*: 2023-03-14 |
Sponsor Name:Helse Bergen HF | ||
Full Title: Diagnostic treatment-trial for autonomous cortisol secretion- a tool to select patients for adrenalectomy | ||
Medical condition: autonomous cortisol secretion | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NO (Trial now transitioned) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
